Gastric Cancer Screening Using Breath Tests for Volatile Organic Compounds Evaluating Breath Analysis and Microbiota Role in Detection

What this Trial Is About

Researchers are evaluating the potential use of breath volatile organic compounds VOCs to screen for gastric cancer. This study includes patients with confirmed gastric cancer or precancerous lesions, as well as individuals without lesions and those from the general population at average risk. It also explores how lifestyle factors, diet, smoking, and microbiota may affect VOC composition in the breath. Participants will undergo breath sampling using specialized sensor devices or gas chromatography coupled with mass spectroscopy GC-MS. Some gastric cancer patients will provide surgical tissue samples for VOC analysis. Other procedures include routine upper endoscopy with biopsies and collection of gastric and fecal samples to analyze the microbiota and its relationship with breath VOCs. Pepsinogen testing will also identify risk for gastric atrophy in some participants. During the study, researchers will identify characteristic VOC patterns for detecting gastric cancer and precancerous lesions over a 2 to 3-year period. They will assess the best-performing sensors and correlate VOCs with microbiota and metabolome data. Participants will be monitored with breath tests, endoscopies done when clinically indicated, and microbiota analysis. The study is conducted at clinical sites in Europe and Latin America and follows participants for up to three years after recruitment begins.

Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach